Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Predicting the course of Alzheimer's progression.

Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC; Alzheimer’s Disease Neuroimaging Initiative.

Brain Inform. 2019 Jun 28;6(1):6. doi: 10.1186/s40708-019-0099-0.

2.

Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).

Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA.

J Alzheimers Dis. 2019;70(1):131-138. doi: 10.3233/JAD-190322.

PMID:
31156181
3.

Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention.

Rafii MS, Aisen PS.

CNS Drugs. 2019 Feb;33(2):99-106. doi: 10.1007/s40263-018-0598-1.

PMID:
30560544
4.

Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.

Rafii MS.

Dev Neurobiol. 2018 Dec 8. doi: 10.1002/dneu.22658. [Epub ahead of print] Review.

PMID:
30536948
5.

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative.

Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC.

Alzheimers Dement (Amst). 2018 Aug 29;10:657-668. doi: 10.1016/j.dadm.2018.07.008. eCollection 2018.

6.

Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome.

Rafii MS, Santoro SL.

JAMA Neurol. 2018 Nov 19. doi: 10.1001/jamaneurol.2018.3443. [Epub ahead of print] No abstract available.

PMID:
30452497
7.

Diagnostic biomarkers of Alzheimer's disease in Down syndrome.

Rafii MS.

Lancet Neurol. 2018 Oct;17(10):831-832. doi: 10.1016/S1474-4422(18)30293-X. Epub 2018 Aug 29. No abstract available.

PMID:
30172623
8.

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.

9.

Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS; AAV2-NGF Study Team.

JAMA Neurol. 2018 Jul 1;75(7):834-841. doi: 10.1001/jamaneurol.2018.0233.

10.

PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).

Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC; Down Syndrome Biomarker Initiative and the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;60(2):439-450. doi: 10.3233/JAD-170390.

PMID:
28946567
11.

Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS.

Alzheimers Dement (N Y). 2016 Jun;2(2):69-81. doi: 10.1016/j.trci.2016.02.004.

12.

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.

Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernández S, Videla L, Sala I, Sánchez-Saudinós MB, Morenas-Rodriguez E, Ribosa-Nogué R, Illán-Gala I, Gonzalez-Ortiz S, Clarimón J, Schmitt F, Powell DK, Bosch B, Lladó A, Rafii MS, Head E, Molinuevo JL, Blesa R, Videla S, Lleó A, Sánchez-Valle R, Fortea J.

Alzheimers Dement. 2017 Nov;13(11):1251-1260. doi: 10.1016/j.jalz.2017.03.007. Epub 2017 Apr 29.

13.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.

Rafii MS, Skotko BG, McDonough ME, Pulsifer M, Evans C, Doran E, Muranevici G, Kesslak P, Abushakra S, Lott IT; ELND005-DS Study Group.

J Alzheimers Dis. 2017;58(2):401-411. doi: 10.3233/JAD-160965.

14.

Outcome Measures for Clinical Trials in Down Syndrome.

Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, d'Ardhuy XL, Capone G, Conners FA, Mervis CB, Abbeduto L, Rafii MS, Krinsky-McHale SJ, Urv T; Outcome Measures Working Group.

Am J Intellect Dev Disabil. 2017 May;122(3):247-281. doi: 10.1352/1944-7558-122.3.247.

15.

A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

16.

Targeting tau protein in Alzheimer's disease.

Rafii MS.

Lancet. 2016 Dec 10;388(10062):2842-2844. doi: 10.1016/S0140-6736(16)32107-9. Epub 2016 Nov 16. No abstract available.

PMID:
27863808
17.

Improving Memory and Cognition in Individuals with Down Syndrome.

Rafii MS.

CNS Drugs. 2016 Jul;30(7):567-73. doi: 10.1007/s40263-016-0353-4. Review.

PMID:
27272473
18.

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA.

Front Behav Neurosci. 2015 Sep 14;9:239. doi: 10.3389/fnbeh.2015.00239. eCollection 2015.

19.

Advances in Alzheimer's disease drug development.

Rafii MS, Aisen PS.

BMC Med. 2015 Mar 25;13:62. doi: 10.1186/s12916-015-0297-4. Review.

20.

Active Immunotherapy for Alzheimer's Disease: The Road Ahead.

Rafii MS.

J Prev Alzheimers Dis. 2015 Jun;2(2):78-79. doi: 10.14283/jpad.2015.59. Epub 2015 Apr 15. No abstract available.

21.

Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?

Rafii MS.

Alzheimers Res Ther. 2014 Sep 12;6(5-8):60. doi: 10.1186/s13195-014-0060-7. eCollection 2014.

22.

Preclinical Alzheimer's disease therapeutics.

Rafii MS.

J Alzheimers Dis. 2014;42 Suppl 4:S545-9. doi: 10.3233/JAD-141482. Review.

PMID:
25079804
23.

A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.

Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, Bartus RT.

Alzheimers Dement. 2014 Sep;10(5):571-81. doi: 10.1016/j.jalz.2013.09.004. Epub 2014 Jan 7.

PMID:
24411134
24.

Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease.

Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS.

Am J Alzheimers Dis Other Demen. 2014 Mar;29(2):159-65. doi: 10.1177/1533317513507373. Epub 2013 Oct 27.

25.

Update on Alzheimer's disease therapeutics.

Rafii MS.

Rev Recent Clin Trials. 2013 Jun;8(2):110-8. Review.

PMID:
23859061
26.

The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities.

Moran JA, Rafii MS, Keller SM, Singh BK, Janicki MP; American Academy of Developmental Medicine and Dentistry; Rehabilitation Research and Training Center on Aging With Developmental Disabilities, University of Illinois at Chicago; American Association on Intellectual and Developmental Disabilities.

Mayo Clin Proc. 2013 Aug;88(8):831-40. doi: 10.1016/j.mayocp.2013.04.024. Epub 2013 Jul 10.

PMID:
23849993
27.

An expanded role for neuroimaging in the evaluation of memory impairment.

Desikan RS, Rafii MS, Brewer JB, Hess CP.

AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2075-82. doi: 10.3174/ajnr.A3644. Epub 2013 Jun 13.

28.

A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Apr 19;76(16):1389-94. doi: 10.1212/WNL.0b013e318216eb7b.

29.

Comparison of the memory performance index with standard neuropsychological measures of cognition.

Rafii MS, Taylor C, Coutinho A, Kim K, Galasko D.

Am J Alzheimers Dis Other Demen. 2011 May;26(3):235-9. doi: 10.1177/1533317511402316. Epub 2011 Mar 15.

30.

Functional brain imaging in the clinical assessment of consciousness.

Rafii MS, Brewer JB.

PLoS Biol. 2010 Nov 30;8(11):e1000548. doi: 10.1371/journal.pbio.1000548.

31.

The pulse of drug development for Alzheimer's disease.

Rafii MS.

Rev Recent Clin Trials. 2010 Jan;5(1):57-62. Review.

PMID:
20205688
32.

High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment.

Kovacevic S, Rafii MS, Brewer JB; Alzheimer's Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):139-45. doi: 10.1097/WAD.0b013e318192e745.

33.

Recent developments in Alzheimer's disease therapeutics.

Rafii MS, Aisen PS.

BMC Med. 2009 Feb 19;7:7. doi: 10.1186/1741-7015-7-7. Review.

34.

Primary care screening for dementia and mild cognitive impairment.

Rafii MS, Galasko D.

JAMA. 2008 Mar 12;299(10):1132; author reply 1133-4. doi: 10.1001/jama.299.10.1132-a. No abstract available.

PMID:
18334686
35.

Case 14: a woman with bilateral Bell's palsy.

Rafii MS.

MedGenMed. 2006 Oct 31;8(4):23. No abstract available.

36.

Compendium of cerebrovascular diseases.

Rafii MS, Hillis AE.

Int Rev Psychiatry. 2006 Oct;18(5):395-407. Review.

PMID:
17085359
37.

Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development.

Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR.

J Cell Physiol. 2006 Nov;209(2):439-47.

38.

Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS.

Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC, Fallon JR.

FASEB J. 2006 Aug;20(10):1724-6. Epub 2006 Jun 28.

39.

Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke.

Rafii MS, Koenig M, Ziai WC.

Neurology. 2005 Dec 27;65(12):1906. No abstract available.

PMID:
16380611
40.

Agrin and microvascular damage in Alzheimer's disease.

Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG.

Neurobiol Aging. 2000 Mar-Apr;21(2):349-55.

PMID:
10867220
41.

Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma.

Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG.

Proc Natl Acad Sci U S A. 1999 May 25;96(11):6468-72.

42.
43.

Evidence for a postnatal doubling of neuron number in the developing human cerebral cortex between 15 months and 6 years.

Shankle WR, Landing BH, Rafii MS, Schiano A, Chen JM, Hara J.

J Theor Biol. 1998 Mar 21;191(2):115-40.

PMID:
9631564

Supplemental Content

Loading ...
Support Center